الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 105 |  |  |
| | | from | 105 | | |
Abstract
Pre-eclampsia is a serious disorder complicating pregnancy. It has grave consequences on both maternal and neonatal health with increasing morbidity and mortality. This figure is further accentuated in developing countries when compared with the developed worlds. Till now, delivery of the placenta is considered the only definite cure. Recent discoveries have led to important advances in understanding the pathogenesis of the condition. The central hypothesis is defective spiral artery remodeling, which causes ischemia of the placenta with increased oxidative stress, leading to widespread endothelial dysfunction, affecting all the maternal organ systems. Management of severe preeclampsia includes control of severe hypertension, prevention and treatment of eclamptic seizures and expedited delivery by induction of labor or caesarean section.
The present study was designed to evaluate the effect of nifedipine, nicorandil and coenzyme Q10 used either alone or in combinations on severe preeclampsia.
The study was conducted at the Obstetrics and Gynecology Hospital of Alexandria University on 140 patients diagnosed as severe preeclampsia after taking their informed written consent, chosen according to certain inclusion and exclusion criteria. After being subjected to history taking, full clinical examination and Doppler US, blood samples were collected to assess levels of SOD, MDA, eNOS and platelet aggregation.
They were randomly assigned to four groups, each of 35 patients. First group received nifedipine (10 mg) tablets orally three times daily. Second group received nicorandil (20 mg) tablets orally twice daily. Third group received nifedipine (10 mg) tablets orally three times daily + coenzyme Q10 (100 mg) softgels orally twice daily. Fourth group received nicorandil (20 mg) tablets orally twice daily + coenzyme Q10 (100 mg) softgels orally twice daily.